Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes

Clinical Infectious Diseases

Volumn 63, Issue 3, 2016, Pages 300-309

  Self, Wesley H ^a   Wunderink, Richard G ^b   Williams, Derek J ^a   Zhu, Yuwei ^a   Anderson, Evan J ^c   Balk, Robert A ^d   Fakhran, Sherene S ^e   Chappell, James D ^a   Casimir, Geoffrey ^a   Courtney, D Mark ^b   Trabue, Christopher ^f   Waterer, Grant W ^b,g   Bramley, Anna ^h   Magill, Shelley ^h   Jain, Seema ^h   Edwards, Kathryn M ^a   Grijalva, Carlos G ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e Jr Hospital of Cook County   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

antibiotics; pneumonia; Staphylococcus aureus

Indexed keywords

LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HEMODIALYSIS; HEMOPTYSIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFLUENZA; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCAL PNEUMONIA; VERY ELDERLY; ADOLESCENT; CLINICAL TRIAL; COMMUNITY ACQUIRED INFECTION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; MICROBIOLOGY; PUBLIC HEALTH SERVICE; STAPHYLOCOCCUS AUREUS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COMMUNITY-ACQUIRED INFECTIONS; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PNEUMONIA, STAPHYLOCOCCAL; PREVALENCE; PROSPECTIVE STUDIES; STAPHYLOCOCCUS AUREUS; UNITED STATES; YOUNG ADULT;

EID: 84981268365     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw300     Document Type: Article

References (47)

1. Francis JS, Doherty MC, Lopatin U, et al. Severe community onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentin leukocidin genes. Clin Infect Dis 2005; 40:100-7.
2. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894-9.
3. Kallen AJ, Brunkard J, Moore Z, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009; 53:358-65.
4. Kollef MH, Shorr A, Tabak YP, Gupta V, Lui LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854-62.
5. Kollef MH, Micek ST. Staphylococcus aureus: a superbug infection in community and hospital settings. Chest 2005; 128:1093-7.
6. TadrosM,Williams V, Coleman BL, et al. Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals. Plos One 2013; 8:e75171.
7. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis 2012; 54:1126-33.
8. Lobo JL, Reed KD, Wunderink RG. Expanded clinical presentation of communityacquired methicillin-resistant Staphylococcus aureus pneumonia. Chest 2010; 138:130-6.
9. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med 2015; 373:415-27.
10. Postma DF, vanWerkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015; 372:1312-23.
11. Musher DM, Roig IL, Cazares G, Stager CE, Logan N, Safar H. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect 2013; 67:11-8.
12. Fridkin S, Baggs J, Fagan R, et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep 2014; 63:194-200.
13. Rosini JM, Grovola MR, Levine BJ, Jasani NB. Prescribing habits of vancomycin in the emergency department: are we dosing appropriately? J Emerg Med 2013; 44:979-84.
14. Mandell LA, Wunderink R. Methicillin-resistant Staphylococcus aureus and community- acquired pneumonia: an evolving relationship. Clin Infect Dis 2012; 54:1134-6.
15. Griffin AT, Peyrani P, Wiemken TL, Ramirez JA, Arnold FW. Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia. Infection 2013; 41:517-23.
16. Self WH, Wunderink RG, Williams DJ, Barrett TW, Baughman AH, Grijalva CG. Comparison of clinical prediction models for resistant bacteria in communityonset pneumonia. Acad Emerg Med 2015; 22:730-40.
17. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(suppl 2): S27-72.
18. Shindo Y, Ryota I, Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Resp Crit Care Med 2013; 188:985-95.
19. Jung WJ, Kang YA, Park MS, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia. BMC Infect Dis 2013; 13:370.
20. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies in the aged: the index of ADL: a standardized measure of biological and psychological function. JAMA 1963; 185:914-9.
21. Bartlett RC. Medical microbiology: quality, cost and clinical relevance. New York: John Wiley, 1974:24-31.
22. Murdoch DR, Laing RTR, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001; 39:3495-8.
23. Murdoch DR. Diagnosis of Legionella infection. Clin Infect Dis 2003; 36:64-9.
24. Thurman KA,Warner AK, Cowart KC, Benitez AJ,Winchell JM. Detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella spp. in clinical specimens using a single-tube multiplex real-time PCR assay. Diagn Microbiol Infect Dis 2011; 70:1-9.
25. Carvalho MGS, Tondella ML, Mc-Caustland K, et al. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol 2007; 45:2460-6.
26. Blaschke AJ, Heyrend C, Byington CL, et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J 2011; 30:289-94.
27. Blaschke AJ, Heyrend C, Byington CL, et al. Rapid identification of pathogens from positive blood cultures by multiplex polymerase chain reaction using the FilmArray system. Diagn Microbiol Infect Dis 2012; 74:349-55.
28. Weinberg GA, Schnabel KC, Erdman DD, et al. Field evaluation of TaqMan Array Card (TAC) for the simultaneous detection of multiple respiratory viruses in children with acute respiratory infection. J Clin Virol 2013; 57:254-60.
29. Dare RK, Fry AM, Chittaganpitch M, Sawanpanyalert P, Olsen SJ, Erdman DD. Human coronavirus infections in rural Thailand: a comprehensive study using real-time reverse-transcription polymerase chain reaction assays. J Infect Dis 2007; 196:1321-8.
30. Sawatwong P, Chittaganpitch M, Hall H, et al. Serology as an adjunct to polymerase chain reaction assays for surveillance of acute respiratory virus infections. Clin Infect Dis 2012; 54:445-6.
31. Feikin DR, Njenga MK, Bigogo G, et al. Additional diagnostic yield of adding serology to PCR in diagnosing viral acute respiratory infections in Kenyan patients 5 years of age and older. Clin Vaccine Immunol 2013; 20:113-4.
32. Jorgensen J, Pfaller M, Carroll K, et al. Manual of clinical microbiology. 11th edition. Washington, DC: ASM Press, 2015.
33. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. CLSI document M100- S22. Wayne, PA: Clinical and Laboratory Standards Committee, 2012.
34. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-50.
35. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377-82.
36. Maruyama T, Fujisawa T, OkunoM, et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug resistant pathogens to select initial empiric therapy. Clin Infect Dis 2013; 57:1373-83.
37. Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012; 54:193-8.
38. Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug- resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012; 54:470-8.
39. Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis 2013; 13:268.
40. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54:4851-63.
41. Flanders SA, Saint S. Why does antimicrobial overuse in hospitalized patients persist? JAMA Intern Med 2014; 174:661-2.
42. Caliendo AM, Gilbert DN, Ginocchio CC, et al. Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis 2013; 57(suppl 3):S139-70.
43. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community- acquired pneumonia caused by Staphylococcus aureus containing Panton- Valentine leukocidin. Clin Infect Dis 2007; 45:315-21.
44. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:355-9.
45. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
46. Fujitani S, Yu VL. A new category-healthcare-associated pneumonia: a good idea, but problems with its execution. Eur J Clin Microbiol Infect Dis 2006; 25:627-31.
47. Wunderink RG. Healthcare-associated bacteremia: stirring the mud. Crit Care Med 2006; 34:2685-6.